Denodo’s 2020 User Conference DataFest Draws a Record 1,800 Global Attendees Exploring Hybrid/Multi-Cloud, Cloud Integration, Data Fabric, Data Science & AI/ML
17.12.2020 11:00:00 EET | Business Wire | Press release
Denodo, the leader in data virtualization, today announced a record attendance of nearly 1,800 at its annual user conference, DataFest 2020 which was held across the NA, EMEA, and APAC regions. This year’s virtual DataFest events hosted some of the most well recognized data luminaries and subject matter experts, who immersed themselves in topics such as hybrid/multi-cloud strategies, cloud data integration, data science and AI/ML, among others. Attendees made up of Denodo customers, partners, and analysts chose the winners of Denodo’s annual Data Innovation Awards at each event, to recognize some of the exemplary use cases of logical data fabric created with data virtualization technology as the foundation.
All of the session presentations are now available for on-demand viewing, here.
“Our heartiest congratulations go out to all the winners and finalists of our Data Innovation Awards,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “Recognizing these customers is the least we can do, as these organizations and individuals set the standard for the future of data management and exemplify some of the best use cases of logical data fabric. As we push the envelope with continuous product innovations, our customers showcased how those advancements can be put to work for even more impressive and valuable use cases.”
Like past events, this year included an esteemed panel of subject matter experts, who distilled through a slew of customer use cases to choose the finalists for each Data Innovation Award. All Denodo customers were considered for the Data Innovation Award with the winners acknowledged for demonstrating best practices, business impact, and novel implementations. The selection process highlights the many innovative uses of data virtualization at actual customer sites and provided attendees with metrics to validate its importance.
“I am absolutely thrilled to receive this year’s Data Innovation Award for the EMEA region,” said Olav Lognvik, Solution Architect at DNB. “Denodo has been the central piece in our cutting-edge data platform that supports data science use cases such as the one for mobile banking. We are glad to be able to share our success story with hundreds of data virtualization enthusiasts and as we broaden our use cases of the Denodo Platform, we hope to share more success stories in the future.”
Winners and finalists of the Denodo Data Innovation Awards 2020 include:
North America – Winner Lauren Cordova from Panasonic, for its connected car IoT/Edge and cloud analytics use case; finalist Ryan Thompson from Prologis, for their logical data lake use case.
EMEA – Winner Olav Lognvik and Christian Dancke Tuen from DNB, for its data science for mobile banking use case; finalist Tekin Mentes from LeasePlan, for their global data hub for fleet management use case.
APAC – Winner Joshua Fletcher from BHP, for its multi-cloud data fabric for global resource management use case; finalist Johan De Coning from Silver Chain, for their Healthcare with hololens and incident management system use case.
Please tweet: News: #datavirtualization leader Denodo announces the winners of its 3rd annual Data Innovation Awards during #DenodoDataFest 2020. Audience vote @Panasonic, @BHP and @DNB for the most innovative use cases.
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005044/en/
Contact information
Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom